Physician profile
Irene A Bailey
NPI 1023116894
$4,051.43
in general payments reported to CMS, 2019-2025
27 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $555 · 2021: $751 · 2022: $552 · 2023: $673 · 2024: $686 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $672.33 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $575.40 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $496.58 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $299.27 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $217.34 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.10 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $126.48 | 2020-2021 | |
| Genentech USA, INC. | $123.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $71.04 | 2019-2023 | |
| Dexcom, INC. | $66.30 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $64.59 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $61.67 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.81 | 2019-2021 | |
| Horizon Therapeutics Plc | $41.80 | 2023 | Krystexxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.80 | 2022 | |
| Ossur Americas, INC. | $26.50 | 2025 | |
| Merck Sharp & Dohme LLC | $25.75 | 2020 | |
| Nestle Healthcare Nutrition INC. | $19.79 | 2023 | |
| Abbvie INC. | $18.72 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.50 | 2022 | |
| Hologic Sales and Service, LLC | $17.04 | 2019 | |
| Esperion Therapeutics, INC. | $16.63 | 2021 | |
| Allergan, INC. | $16.15 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.59 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.